Stockscreener 앱 받기
3.05
0.65%
-0.02
시간 외 거래:
3.06
0.01
+0.33%
전일 마감가:
$3.07
열려 있는:
$3.08
하루 거래량:
4.04M
Relative Volume:
1.21
시가총액:
$848.79M
수익:
-
순이익/손실:
$-244.17M
주가수익비율:
-3.124
EPS:
-0.9763
순현금흐름:
$-144.77M
1주 성능:
-0.33%
1개월 성능:
-7.29%
6개월 성능:
-24.13%
1년 성능:
+53.27%
1일 변동 폭
$2.97
$3.17
1주일 범위
$2.97
$3.245
52주 변동 폭
$1.975
$6.55
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.05 | 854.36M | 0 | -244.17M | -144.77M | -0.9763 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | Wedbush | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-03-18 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-01-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-11-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 개시 | Rodman & Renshaw | Buy |
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
RA Capital affiliates report 18.75M Sana Biotechnology shares (NASDAQ: SANA) - Stock Titan
Sana Biotechnology | SCHEDULE 13G: Others - Moomoo
SANA Stock Chart | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $3.07 - Moomoo
InvestingPro Fair Value spotted Sana Biotech overvaluation early By Investing.com - Investing.com Canada
Sana Biotechnology raises $69M through ATM share sale - MSN
Sana Biotech rises as Mayo Clinic partners for diabetes therapy - MSN
Sana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market Facility - Moomoo
Sana Biotechnology Raises $69 Million Through Equity Offering - TipRanks
Sana Biotechnology (SANA) sells 21.6M shares to raise about $69M - Stock Titan
Sana Biotechnology | 8-K: Current report - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Sana Biotechnology Raises $69 Million Through ATM Equity Offering - Moomoo
Sana Biotechnology raises $69 million through stock sale By Investing.com - Investing.com Australia
Sana Biotechnology raises $69 million through stock sale - Investing.com
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through Its At-the-Market (ATM) Facility - 富途牛牛
Sana presents preclinical data on in vivo CAR T therapy SG293 - Investing.com UK
Sana presents preclinical data on in vivo CAR T therapy SG293 By Investing.com - Investing.com India
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
SANA: Progress in gene-edited islet and in vivo CAR-T therapies positions the pipeline for major milestones - TradingView
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs - The Manila Times
Sana Biotechnology Presents Preclinical Data for In Vivo - GlobeNewswire
A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $16 - Moomoo
Sana Biotechnology | 10-Q: Q1 2026 Earnings Report - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss By Investing.com - Investing.com South Africa
Sana Biotechnology | 8-K: Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - Moomoo
Sana Biotechnology gains on Mayo Clinic partnership progress despite EPS miss - Investing.com India
Sana: Q1 Earnings Snapshot - kare11.com
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q1 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.16 - marketscreener.com
Sana Biotechnology | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Sana Biotechnology (SANA) Q1 2026 loss widens cash risk despite Mayo deal - Stock Titan
Mayo collaboration and Q1 2026 results for Sana (NASDAQ: SANA) - Stock Titan
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates - ChartMill
Rodman & Renshaw initiates Sana Biotechnology stock with buy rating - Investing.com
Rodman & Renshaw initiates Sana Biotechnology stock with buy rating By Investing.com - Investing.com Canada
Is Sana Biotechnology’s (SANA) Options Spike Before Earnings Hinting at a Repriced Cell Therapy Story? - simplywall.st
Sana Biotechnology (SANA) Valuation Check As Conference Update And Partnerships Keep Investor Focus High - Sahm
MSN Money - MSN
Sana Biotechnology (SANA) Investor Outlook: A 144.90% Upside Potential In Innovative Cell Therapy - DirectorsTalk Interviews
Sana Biotechnology (SANA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Sana CEO Steve Harr to give business update in May 12 webcast - Stock Titan
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference - The Manila Times
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):